Structural and Functional Impairments of Reconstituted High-Density Lipoprotein by Incorporation of Recombinant β-Amyloid42
Overview
Authors
Affiliations
Beta (β)-amyloid (Aβ) is a causative protein of Alzheimer's disease (AD). In the pathogenesis of AD, the apolipoprotein (apo) A-I and high-density lipoprotein (HDL) metabolism is essential for the clearance of Aβ. In this study, recombinant Aβ42 was expressed and purified via the pET-30a expression vector and production system to elucidate the physiological effects of Aβ on HDL metabolism. The recombinant human Aβ protein (51 aa) was purified to at least 95% purity and characterized in either the lipid-free and lipid-bound states with apoA-I. Aβ was incorporated into the reconstituted HDL (rHDL) (molar ratio 95:5:1, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC):cholesterol:apoA-I) with various apoA-I:Aβ ratios from 1:0 to 1:0.5, 1:1 and 1:2. With an increasing molar ratio of Aβ, the α-helicity of apoA-I was decreased from 62% to 36% with a red shift of the Trp wavelength maximum fluorescence from 337 to 340 nm in apoA-I. The glycation reaction of apoA-I was accelerated further by the addition of Aβ. The treatment of fructose and Aβ caused more multimerization of apoA-I in the lipid-free state and in HDL. The phospholipid-binding ability of apoA-I was impaired severely by the addition of Aβ in a dose-dependent manner. The phagocytosis of LDL into macrophages was accelerated more by the presence of Aβ with the production of more oxidized species. Aβ severely impaired tissue regeneration, and a microinjection of Aβ enhanced embryotoxicity. In conclusion, the beneficial functions of apoA-I and HDL were severely impaired by the addition of Aβ via its detrimental effect on secondary structure. The impairment of HDL functionality occurred more synergistically by means of the co-addition of fructose and Aβ.
Wang T, Zheng R, Zhang S, Qin H, Jin H, Teng Y Sci Rep. 2024; 14(1):25769.
PMID: 39468327 PMC: 11519474. DOI: 10.1038/s41598-024-77813-9.
Cho K, Kim J, Kang D, Dominguez-Horta M, Martinez-Donato G Pharmaceuticals (Basel). 2024; 17(2).
PMID: 38399381 PMC: 10892825. DOI: 10.3390/ph17020165.
Luo Y, Tan X, Zhang X, Li Y, Huang J, Deng Y Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(10):1324-1331.
PMID: 36411683 PMC: 10930358. DOI: 10.11817/j.issn.1672-7347.2022.210770.
Cho K Molecules. 2022; 27(13).
PMID: 35807498 PMC: 9268363. DOI: 10.3390/molecules27134255.
Cho K Int J Mol Sci. 2022; 23(7).
PMID: 35409326 PMC: 8999423. DOI: 10.3390/ijms23073967.